| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biomedical Research | 12 | 2023 | 467 | 3.250 |
Why?
|
| Hypertension | 29 | 2025 | 823 | 3.080 |
Why?
|
| Antihypertensive Agents | 16 | 2025 | 285 | 2.200 |
Why?
|
| Minority Groups | 12 | 2023 | 663 | 2.090 |
Why?
|
| Heart Failure | 16 | 2017 | 298 | 1.600 |
Why?
|
| Tetrazoles | 10 | 2013 | 45 | 1.400 |
Why?
|
| Self Care | 4 | 2019 | 173 | 1.370 |
Why?
|
| Hydrochlorothiazide | 9 | 2013 | 16 | 1.280 |
Why?
|
| Mentors | 5 | 2023 | 143 | 1.220 |
Why?
|
| Blood Pressure | 18 | 2025 | 662 | 1.220 |
Why?
|
| Minority Health | 4 | 2023 | 96 | 1.200 |
Why?
|
| Cardiovascular Diseases | 13 | 2022 | 729 | 1.200 |
Why?
|
| Isosorbide Dinitrate | 7 | 2017 | 9 | 1.110 |
Why?
|
| Humans | 101 | 2025 | 42163 | 1.070 |
Why?
|
| Diuretics | 9 | 2015 | 51 | 0.910 |
Why?
|
| Hypertrophy, Left Ventricular | 6 | 2011 | 45 | 0.870 |
Why?
|
| Blood Glucose | 6 | 2022 | 386 | 0.860 |
Why?
|
| Hydralazine | 6 | 2017 | 7 | 0.850 |
Why?
|
| United States | 33 | 2024 | 5072 | 0.800 |
Why?
|
| Diabetes Mellitus | 5 | 2022 | 532 | 0.780 |
Why?
|
| Georgia | 10 | 2019 | 189 | 0.750 |
Why?
|
| Research Support as Topic | 3 | 2019 | 89 | 0.740 |
Why?
|
| Middle Aged | 46 | 2025 | 11819 | 0.740 |
Why?
|
| Cooperative Behavior | 4 | 2018 | 250 | 0.740 |
Why?
|
| Biphenyl Compounds | 5 | 2008 | 52 | 0.720 |
Why?
|
| Research Personnel | 3 | 2022 | 191 | 0.710 |
Why?
|
| Female | 60 | 2025 | 24018 | 0.710 |
Why?
|
| Telemedicine | 2 | 2018 | 215 | 0.690 |
Why?
|
| Aged | 37 | 2025 | 7982 | 0.670 |
Why?
|
| Amlodipine | 6 | 2013 | 20 | 0.660 |
Why?
|
| Vulnerable Populations | 2 | 2019 | 163 | 0.640 |
Why?
|
| Patient-Centered Care | 2 | 2018 | 73 | 0.630 |
Why?
|
| Research | 1 | 2021 | 177 | 0.620 |
Why?
|
| Valine | 4 | 2013 | 29 | 0.620 |
Why?
|
| Organizational Policy | 1 | 2019 | 26 | 0.620 |
Why?
|
| Medical Informatics | 1 | 2019 | 24 | 0.610 |
Why?
|
| Internet | 2 | 2011 | 234 | 0.600 |
Why?
|
| Peer Review, Research | 1 | 2018 | 15 | 0.590 |
Why?
|
| Behavioral Research | 1 | 2019 | 41 | 0.590 |
Why?
|
| Male | 51 | 2025 | 22779 | 0.580 |
Why?
|
| Leadership | 1 | 2019 | 84 | 0.580 |
Why?
|
| Research Subjects | 1 | 2018 | 34 | 0.570 |
Why?
|
| Medicare | 2 | 2019 | 326 | 0.570 |
Why?
|
| Drug Therapy, Combination | 13 | 2017 | 233 | 0.570 |
Why?
|
| Healthcare Disparities | 5 | 2018 | 573 | 0.560 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 4 | 2013 | 37 | 0.550 |
Why?
|
| Prospective Studies | 11 | 2023 | 1574 | 0.540 |
Why?
|
| Treatment Outcome | 17 | 2025 | 1586 | 0.500 |
Why?
|
| Societies, Medical | 3 | 2015 | 74 | 0.500 |
Why?
|
| Women's Health | 3 | 2011 | 158 | 0.470 |
Why?
|
| Adult | 30 | 2022 | 13458 | 0.470 |
Why?
|
| Universities | 3 | 2020 | 539 | 0.460 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2018 | 959 | 0.460 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2019 | 744 | 0.450 |
Why?
|
| Research Design | 4 | 2018 | 370 | 0.440 |
Why?
|
| Vasodilator Agents | 6 | 2013 | 55 | 0.430 |
Why?
|
| Nitric Oxide Synthase | 2 | 2005 | 134 | 0.430 |
Why?
|
| Double-Blind Method | 13 | 2025 | 305 | 0.420 |
Why?
|
| Academies and Institutes | 1 | 2013 | 39 | 0.410 |
Why?
|
| Obesity, Abdominal | 1 | 2013 | 29 | 0.390 |
Why?
|
| Registries | 4 | 2019 | 431 | 0.390 |
Why?
|
| Echocardiography | 6 | 2015 | 167 | 0.390 |
Why?
|
| Nitric Oxide | 2 | 2007 | 381 | 0.380 |
Why?
|
| Drug Combinations | 9 | 2017 | 102 | 0.370 |
Why?
|
| Blood Glucose Self-Monitoring | 2 | 2012 | 33 | 0.360 |
Why?
|
| Community-Institutional Relations | 1 | 2013 | 208 | 0.360 |
Why?
|
| Health Status Disparities | 2 | 2019 | 705 | 0.360 |
Why?
|
| Receptors, Angiotensin | 1 | 2011 | 15 | 0.350 |
Why?
|
| Cultural Diversity | 4 | 2020 | 187 | 0.340 |
Why?
|
| Risk Factors | 14 | 2020 | 3942 | 0.340 |
Why?
|
| Coronary Angiography | 3 | 2011 | 97 | 0.330 |
Why?
|
| Nitric Oxide Donors | 2 | 2007 | 41 | 0.320 |
Why?
|
| Quality of Health Care | 3 | 2019 | 158 | 0.320 |
Why?
|
| Ventricular Dysfunction, Left | 5 | 2015 | 96 | 0.320 |
Why?
|
| Writing | 2 | 2020 | 41 | 0.310 |
Why?
|
| Government Programs | 2 | 2020 | 29 | 0.310 |
Why?
|
| Cardiology | 3 | 2017 | 19 | 0.310 |
Why?
|
| Community Networks | 2 | 2006 | 106 | 0.300 |
Why?
|
| Myocardial Infarction | 2 | 2011 | 242 | 0.300 |
Why?
|
| Atherosclerosis | 2 | 2008 | 164 | 0.290 |
Why?
|
| Health Education | 2 | 2002 | 358 | 0.280 |
Why?
|
| Coronary Disease | 2 | 2005 | 123 | 0.270 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2008 | 77 | 0.270 |
Why?
|
| Schools, Medical | 2 | 2011 | 208 | 0.270 |
Why?
|
| Thrombosis | 1 | 2008 | 81 | 0.270 |
Why?
|
| Computer Communication Networks | 2 | 2019 | 12 | 0.270 |
Why?
|
| Health Services Accessibility | 2 | 2005 | 680 | 0.260 |
Why?
|
| Heart Ventricles | 3 | 2015 | 123 | 0.260 |
Why?
|
| Aged, 80 and over | 11 | 2013 | 2803 | 0.250 |
Why?
|
| Program Development | 3 | 2018 | 237 | 0.250 |
Why?
|
| Health Services Research | 3 | 2018 | 161 | 0.250 |
Why?
|
| Ventricular Remodeling | 1 | 2007 | 58 | 0.250 |
Why?
|
| National Institutes of Health (U.S.) | 5 | 2022 | 106 | 0.240 |
Why?
|
| Electronic Health Records | 2 | 2019 | 99 | 0.240 |
Why?
|
| Obesity | 5 | 2020 | 1131 | 0.240 |
Why?
|
| Endothelium, Vascular | 2 | 2005 | 261 | 0.240 |
Why?
|
| Simvastatin | 1 | 2005 | 29 | 0.230 |
Why?
|
| Conflict of Interest | 1 | 2004 | 11 | 0.230 |
Why?
|
| Dyslipidemias | 1 | 2005 | 48 | 0.220 |
Why?
|
| Human Experimentation | 1 | 2004 | 11 | 0.220 |
Why?
|
| Coronary Circulation | 3 | 2005 | 29 | 0.220 |
Why?
|
| Ethics, Medical | 1 | 2004 | 18 | 0.220 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 3 | 2025 | 65 | 0.220 |
Why?
|
| Advisory Committees | 1 | 2004 | 34 | 0.220 |
Why?
|
| Health Promotion | 2 | 2010 | 691 | 0.220 |
Why?
|
| Retrospective Studies | 6 | 2017 | 2485 | 0.210 |
Why?
|
| Clinical Trials as Topic | 2 | 2006 | 249 | 0.210 |
Why?
|
| Patient Education as Topic | 4 | 2018 | 234 | 0.210 |
Why?
|
| Education, Medical | 1 | 2005 | 117 | 0.200 |
Why?
|
| Community Health Services | 3 | 2018 | 207 | 0.200 |
Why?
|
| Focus Groups | 2 | 2018 | 398 | 0.200 |
Why?
|
| Primary Health Care | 3 | 2018 | 362 | 0.200 |
Why?
|
| Socioeconomic Factors | 3 | 2005 | 1221 | 0.200 |
Why?
|
| Pilot Projects | 2 | 2019 | 733 | 0.200 |
Why?
|
| Capacity Building | 1 | 2023 | 99 | 0.190 |
Why?
|
| Sex Factors | 6 | 2017 | 1008 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 3 | 2015 | 225 | 0.180 |
Why?
|
| Genomics | 1 | 2024 | 289 | 0.180 |
Why?
|
| Delivery of Health Care | 1 | 2005 | 309 | 0.180 |
Why?
|
| Nitric Oxide Synthase Type III | 3 | 2008 | 74 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2012 | 358 | 0.180 |
Why?
|
| Maryland | 1 | 2021 | 61 | 0.170 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2025 | 1112 | 0.170 |
Why?
|
| Hospitalization | 4 | 2015 | 482 | 0.160 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2000 | 22 | 0.160 |
Why?
|
| Physicians | 2 | 2019 | 180 | 0.160 |
Why?
|
| Biostatistics | 1 | 2018 | 10 | 0.150 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2006 | 78 | 0.140 |
Why?
|
| Personnel Selection | 1 | 2018 | 12 | 0.140 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2018 | 10 | 0.140 |
Why?
|
| Overweight | 1 | 2020 | 248 | 0.140 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 1998 | 13 | 0.140 |
Why?
|
| Electrocardiography | 3 | 2011 | 184 | 0.140 |
Why?
|
| Peer Group | 1 | 2019 | 173 | 0.140 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 90 | 0.140 |
Why?
|
| Off-Label Use | 1 | 2017 | 4 | 0.140 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 50 | 0.140 |
Why?
|
| Education | 1 | 2018 | 60 | 0.140 |
Why?
|
| Mass Screening | 1 | 2002 | 531 | 0.140 |
Why?
|
| Kidney Diseases | 2 | 2013 | 170 | 0.130 |
Why?
|
| Comorbidity | 6 | 2011 | 725 | 0.130 |
Why?
|
| Dipyridamole | 1 | 1997 | 4 | 0.130 |
Why?
|
| Learning | 1 | 2018 | 155 | 0.130 |
Why?
|
| Perception | 1 | 2018 | 209 | 0.130 |
Why?
|
| Counseling | 1 | 2018 | 134 | 0.130 |
Why?
|
| Patient Participation | 1 | 2018 | 87 | 0.130 |
Why?
|
| Exercise Tolerance | 2 | 2015 | 22 | 0.130 |
Why?
|
| Adenosine | 1 | 1997 | 62 | 0.130 |
Why?
|
| Diastole | 3 | 2008 | 47 | 0.130 |
Why?
|
| Age Factors | 4 | 2020 | 1139 | 0.130 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2013 | 19 | 0.120 |
Why?
|
| Intention to Treat Analysis | 2 | 2013 | 14 | 0.120 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 188 | 0.120 |
Why?
|
| Polymorphism, Genetic | 2 | 2008 | 200 | 0.120 |
Why?
|
| Fear | 1 | 2018 | 271 | 0.120 |
Why?
|
| Exercise | 3 | 2018 | 674 | 0.120 |
Why?
|
| Drug Administration Schedule | 2 | 2013 | 153 | 0.120 |
Why?
|
| Xanthine Oxidase | 1 | 2015 | 9 | 0.120 |
Why?
|
| Allopurinol | 1 | 2015 | 13 | 0.120 |
Why?
|
| Hyperuricemia | 1 | 2015 | 13 | 0.110 |
Why?
|
| Students | 1 | 2020 | 617 | 0.110 |
Why?
|
| Motivation | 1 | 2018 | 492 | 0.110 |
Why?
|
| Morbidity | 2 | 2008 | 97 | 0.110 |
Why?
|
| Public Health | 1 | 2018 | 405 | 0.110 |
Why?
|
| Natriuretic Agents | 1 | 2013 | 4 | 0.110 |
Why?
|
| Information Dissemination | 1 | 2014 | 66 | 0.110 |
Why?
|
| Acute Disease | 3 | 2013 | 156 | 0.100 |
Why?
|
| Models, Organizational | 1 | 2013 | 35 | 0.100 |
Why?
|
| Insulin | 2 | 2013 | 255 | 0.100 |
Why?
|
| Health Behavior | 1 | 2018 | 568 | 0.100 |
Why?
|
| Interdisciplinary Communication | 1 | 2013 | 40 | 0.100 |
Why?
|
| Coronary Artery Disease | 2 | 2005 | 164 | 0.100 |
Why?
|
| Ultrafiltration | 1 | 2012 | 2 | 0.100 |
Why?
|
| Follow-Up Studies | 2 | 2011 | 1051 | 0.100 |
Why?
|
| Sulfones | 1 | 2013 | 47 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2005 | 727 | 0.100 |
Why?
|
| Risk Assessment | 5 | 2011 | 845 | 0.100 |
Why?
|
| Piperazines | 1 | 2013 | 117 | 0.090 |
Why?
|
| Prognosis | 3 | 2015 | 850 | 0.090 |
Why?
|
| Hyperglycemia | 1 | 2013 | 60 | 0.090 |
Why?
|
| Dopamine | 1 | 2013 | 272 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2012 | 85 | 0.090 |
Why?
|
| Intra-Abdominal Fat | 1 | 2012 | 45 | 0.090 |
Why?
|
| Prediabetic State | 1 | 2013 | 68 | 0.090 |
Why?
|
| Systole | 2 | 2004 | 67 | 0.090 |
Why?
|
| Multivariate Analysis | 2 | 2011 | 638 | 0.090 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2011 | 5 | 0.090 |
Why?
|
| Furosemide | 1 | 2011 | 10 | 0.090 |
Why?
|
| Killer Cells, Natural | 1 | 2012 | 99 | 0.090 |
Why?
|
| Lymphocyte Activation | 1 | 2012 | 244 | 0.090 |
Why?
|
| Consumer Health Information | 1 | 2011 | 24 | 0.080 |
Why?
|
| Chest Pain | 1 | 2011 | 49 | 0.080 |
Why?
|
| Remote Consultation | 1 | 2010 | 8 | 0.080 |
Why?
|
| Coronary Vessels | 1 | 2011 | 92 | 0.080 |
Why?
|
| Calcium Channel Blockers | 2 | 2010 | 57 | 0.080 |
Why?
|
| Infusions, Intravenous | 3 | 2012 | 55 | 0.080 |
Why?
|
| Financing, Organized | 2 | 2020 | 15 | 0.080 |
Why?
|
| Disease Management | 1 | 2010 | 68 | 0.080 |
Why?
|
| Lactation | 1 | 2008 | 44 | 0.070 |
Why?
|
| Gene Frequency | 2 | 2008 | 203 | 0.070 |
Why?
|
| Adolescent | 5 | 2020 | 5950 | 0.070 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2008 | 31 | 0.070 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2008 | 26 | 0.070 |
Why?
|
| Alcohol Drinking | 2 | 2020 | 585 | 0.070 |
Why?
|
| Body Mass Index | 4 | 2020 | 916 | 0.070 |
Why?
|
| Diffusion of Innovation | 1 | 2008 | 38 | 0.070 |
Why?
|
| Qualitative Research | 1 | 2011 | 526 | 0.070 |
Why?
|
| Interinstitutional Relations | 1 | 2008 | 51 | 0.070 |
Why?
|
| Stroke Volume | 3 | 2015 | 122 | 0.070 |
Why?
|
| Patient Selection | 2 | 2007 | 192 | 0.070 |
Why?
|
| Social Support | 1 | 2011 | 438 | 0.070 |
Why?
|
| Informed Consent | 2 | 2004 | 34 | 0.070 |
Why?
|
| Cardiac Output, Low | 1 | 2006 | 2 | 0.070 |
Why?
|
| South Carolina | 1 | 2006 | 25 | 0.070 |
Why?
|
| Risk Reduction Behavior | 1 | 2008 | 137 | 0.070 |
Why?
|
| Superoxides | 1 | 2007 | 57 | 0.060 |
Why?
|
| Internship and Residency | 2 | 2005 | 141 | 0.060 |
Why?
|
| North Carolina | 1 | 2006 | 122 | 0.060 |
Why?
|
| Kidney Failure, Chronic | 2 | 2005 | 239 | 0.060 |
Why?
|
| Pregnancy | 2 | 2011 | 1737 | 0.060 |
Why?
|
| Interprofessional Relations | 1 | 2006 | 56 | 0.060 |
Why?
|
| Single-Blind Method | 1 | 2006 | 53 | 0.060 |
Why?
|
| Ultrasonography | 2 | 2015 | 132 | 0.060 |
Why?
|
| Medical Audit | 1 | 2006 | 26 | 0.060 |
Why?
|
| Anemia, Sickle Cell | 1 | 2008 | 185 | 0.060 |
Why?
|
| Genotype | 2 | 2008 | 796 | 0.060 |
Why?
|
| Clinical Protocols | 1 | 2005 | 36 | 0.060 |
Why?
|
| Syndrome | 1 | 2005 | 73 | 0.060 |
Why?
|
| Internal Medicine | 1 | 2005 | 32 | 0.060 |
Why?
|
| Europe | 2 | 2015 | 114 | 0.060 |
Why?
|
| Group Practice | 1 | 2005 | 8 | 0.060 |
Why?
|
| Cholesterol, LDL | 1 | 2005 | 73 | 0.060 |
Why?
|
| Creatinine | 3 | 2012 | 102 | 0.060 |
Why?
|
| Troponin T | 1 | 2004 | 10 | 0.060 |
Why?
|
| Referral and Consultation | 1 | 2005 | 141 | 0.060 |
Why?
|
| Mental Competency | 1 | 2004 | 12 | 0.060 |
Why?
|
| Aldosterone | 1 | 2025 | 66 | 0.060 |
Why?
|
| Ambulatory Care | 1 | 2005 | 81 | 0.060 |
Why?
|
| National Human Genome Research Institute (U.S.) | 1 | 2024 | 5 | 0.050 |
Why?
|
| Renal Dialysis | 1 | 2005 | 124 | 0.050 |
Why?
|
| Blood Flow Velocity | 1 | 2004 | 88 | 0.050 |
Why?
|
| Patient Compliance | 1 | 2006 | 225 | 0.050 |
Why?
|
| Insurance Coverage | 1 | 2005 | 108 | 0.050 |
Why?
|
| Vasodilation | 1 | 2004 | 64 | 0.050 |
Why?
|
| Statistics as Topic | 1 | 2004 | 123 | 0.050 |
Why?
|
| Career Choice | 1 | 2004 | 51 | 0.050 |
Why?
|
| Health Status | 2 | 2020 | 432 | 0.050 |
Why?
|
| Alleles | 1 | 2005 | 352 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 3 | 2013 | 144 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2005 | 454 | 0.050 |
Why?
|
| Genome, Human | 1 | 2024 | 143 | 0.050 |
Why?
|
| Sex Distribution | 2 | 2005 | 224 | 0.050 |
Why?
|
| Social Class | 2 | 2011 | 286 | 0.050 |
Why?
|
| Educational Status | 2 | 2020 | 335 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 2005 | 243 | 0.050 |
Why?
|
| Hyperkalemia | 1 | 2002 | 13 | 0.050 |
Why?
|
| Curriculum | 1 | 2005 | 311 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2012 | 2111 | 0.050 |
Why?
|
| Spironolactone | 1 | 2002 | 36 | 0.050 |
Why?
|
| Technology | 1 | 2022 | 28 | 0.050 |
Why?
|
| Exercise Test | 2 | 2015 | 75 | 0.050 |
Why?
|
| Urban Population | 2 | 2005 | 364 | 0.050 |
Why?
|
| Primary Prevention | 1 | 2002 | 63 | 0.050 |
Why?
|
| American Heart Association | 2 | 2011 | 21 | 0.040 |
Why?
|
| Quality of Life | 3 | 2015 | 599 | 0.040 |
Why?
|
| Maternal Mortality | 1 | 2021 | 26 | 0.040 |
Why?
|
| Nigeria | 1 | 2020 | 92 | 0.040 |
Why?
|
| Young Adult | 3 | 2020 | 4936 | 0.040 |
Why?
|
| Intraoperative Care | 1 | 2000 | 13 | 0.040 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2000 | 23 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2005 | 860 | 0.040 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2000 | 26 | 0.040 |
Why?
|
| Mitral Valve | 1 | 2000 | 37 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2000 | 152 | 0.040 |
Why?
|
| Income | 1 | 2020 | 160 | 0.040 |
Why?
|
| Diet | 1 | 2005 | 810 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2022 | 359 | 0.040 |
Why?
|
| Religion and Medicine | 1 | 1999 | 20 | 0.040 |
Why?
|
| Incidence | 1 | 2002 | 1054 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2000 | 143 | 0.040 |
Why?
|
| Mothers | 1 | 2021 | 212 | 0.040 |
Why?
|
| Atenolol | 1 | 1998 | 4 | 0.040 |
Why?
|
| Chlorthalidone | 1 | 1998 | 5 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2000 | 180 | 0.040 |
Why?
|
| Smoking | 1 | 2005 | 1019 | 0.040 |
Why?
|
| Benchmarking | 1 | 2018 | 33 | 0.040 |
Why?
|
| Career Mobility | 1 | 2018 | 29 | 0.040 |
Why?
|
| Physician-Patient Relations | 1 | 1999 | 146 | 0.030 |
Why?
|
| Rural Population | 1 | 2020 | 352 | 0.030 |
Why?
|
| Faculty | 1 | 2018 | 105 | 0.030 |
Why?
|
| Ventricular Function, Left | 1 | 1998 | 111 | 0.030 |
Why?
|
| Hemodynamics | 1 | 1997 | 101 | 0.030 |
Why?
|
| Dogs | 1 | 1997 | 201 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 661 | 0.030 |
Why?
|
| Life Style | 2 | 2011 | 326 | 0.030 |
Why?
|
| Gout Suppressants | 1 | 2015 | 5 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2015 | 8 | 0.030 |
Why?
|
| Cross-Sectional Studies | 2 | 2005 | 3077 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1020 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2008 | 438 | 0.030 |
Why?
|
| Gout | 1 | 2015 | 16 | 0.030 |
Why?
|
| Organizations | 1 | 2014 | 8 | 0.030 |
Why?
|
| Urine | 1 | 2013 | 12 | 0.030 |
Why?
|
| Cystatin C | 1 | 2013 | 25 | 0.030 |
Why?
|
| Outpatients | 1 | 2013 | 34 | 0.030 |
Why?
|
| Purines | 1 | 2013 | 40 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2013 | 111 | 0.020 |
Why?
|
| Efficiency | 1 | 2012 | 14 | 0.020 |
Why?
|
| Walking | 1 | 2013 | 85 | 0.020 |
Why?
|
| Receptors, CXCR3 | 1 | 2012 | 31 | 0.020 |
Why?
|
| Weight Loss | 1 | 2012 | 138 | 0.020 |
Why?
|
| Logistic Models | 2 | 2005 | 1001 | 0.020 |
Why?
|
| Biomedical Engineering | 1 | 2011 | 12 | 0.020 |
Why?
|
| Time Factors | 2 | 2006 | 1848 | 0.020 |
Why?
|
| Kidney | 1 | 2013 | 363 | 0.020 |
Why?
|
| Dyspnea | 1 | 2011 | 23 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2011 | 65 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2011 | 95 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2011 | 98 | 0.020 |
Why?
|
| Glucose Tolerance Test | 1 | 2010 | 76 | 0.020 |
Why?
|
| Telephone | 1 | 2010 | 35 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2011 | 176 | 0.020 |
Why?
|
| Atrial Fibrillation | 1 | 2011 | 121 | 0.020 |
Why?
|
| Algorithms | 1 | 2012 | 508 | 0.020 |
Why?
|
| Pregnancy Complications | 1 | 2011 | 134 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2015 | 990 | 0.020 |
Why?
|
| Introns | 1 | 2008 | 80 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2012 | 1617 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2008 | 90 | 0.020 |
Why?
|
| Dizziness | 1 | 2007 | 6 | 0.020 |
Why?
|
| Arthralgia | 1 | 2007 | 12 | 0.020 |
Why?
|
| Cardiovascular Agents | 1 | 2007 | 24 | 0.020 |
Why?
|
| Hypotension | 1 | 2007 | 25 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2007 | 116 | 0.020 |
Why?
|
| Heart Transplantation | 1 | 2007 | 47 | 0.020 |
Why?
|
| Benzazepines | 1 | 2007 | 33 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2006 | 61 | 0.020 |
Why?
|
| Cause of Death | 1 | 2007 | 183 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2008 | 230 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2008 | 534 | 0.020 |
Why?
|
| Phenotype | 1 | 2008 | 774 | 0.020 |
Why?
|
| Nephrology | 1 | 2005 | 19 | 0.010 |
Why?
|
| Unemployment | 1 | 2005 | 27 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2006 | 362 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2007 | 512 | 0.010 |
Why?
|
| Mortality | 1 | 2007 | 174 | 0.010 |
Why?
|
| Serum Albumin | 1 | 2005 | 58 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2005 | 162 | 0.010 |
Why?
|
| Age of Onset | 1 | 2005 | 115 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2006 | 574 | 0.010 |
Why?
|
| Medically Underserved Area | 1 | 2005 | 118 | 0.010 |
Why?
|
| Age Distribution | 1 | 2005 | 249 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2005 | 225 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2005 | 587 | 0.010 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2004 | 93 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2003 | 107 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2003 | 174 | 0.010 |
Why?
|
| Mexican Americans | 1 | 2005 | 224 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2002 | 61 | 0.010 |
Why?
|
| Stroke | 1 | 2007 | 348 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2005 | 708 | 0.010 |
Why?
|
| Poverty | 1 | 2005 | 395 | 0.010 |
Why?
|
| Alcoholism | 1 | 2005 | 292 | 0.010 |
Why?
|
| Students, Medical | 1 | 2004 | 153 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2002 | 126 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 602 | 0.010 |
Why?
|
| Prevalence | 1 | 2005 | 1597 | 0.010 |
Why?
|
| Animals | 1 | 1997 | 16695 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 2003 | 461 | 0.010 |
Why?
|
| Substance-Related Disorders | 1 | 2005 | 825 | 0.010 |
Why?
|
| Child | 1 | 2005 | 3381 | 0.010 |
Why?
|